• Metastatic Niches

    Disseminated cancer cells engage and manipulate the microenvironment at distant sites and generate a metastatic niche for their own advantage.
    +Read More
  • Experimental Oncology

    Individual cancer cells functionally differ from each other, even in the same patient. We study these differences to develop novel therapeutic strategies.
    +Read More
  • Experimental Hematology

    Cellular aging is inextricably linked to the acquisition of DNA damage which depletes our adult stem cell reserves and directly precipitates age-related diseases including cancer. By understanding the processes via which our stem cells accumulate DNA with age, we can enhance preventative medicine by defining environmental risk factors that lead to DNA damage.
    +Read More
  • 1
  • 2
  • 3

HI-STEM

HI-STEM gGmbH is a non-profit public-private partnership between the German Cancer Research Center (DKFZ) in Heidelberg and the Dietmar Hopp Stiftung.

HI-STEM performs cutting-edge research on stem cells with the aim of translating these results into novel clinical applications. This includes the development of novel diagnostic tools and innovative therapies to monitor and target leukemic and solid tumor stem cells as well as metastatic disease.

HI-STEM was founded in 2008 and is located in newly renovated laboratories and offices within the main building of the DKFZ.

HI-STEM is made up of an international team of more than fifty scientists, including postdoctoral fellows, PhD and MSc. students and technical staff. This research team is spread over five topics and is directed by the managing director of HI-STEM, Professor Andreas Trumpp, as well as four additional group leaders.

The HI-STEM Research Groups:


Researchers at HI-STEM are working in close collaboration with colleagues of the University Clinical Centers in Heidelberg, Mannheim and other cities as well as with the National Center for Tumor Diseases (NCT) in Heidelberg. In addition, HI-STEM collaborates with various biotechnology and pharmaceutical companies to investigate and develop novel strategies to push forward the development of new drugs and effective treatments for different types of cancer and to promote their clinical application.

 

 

           

Contest TW
Contest TW
Contest TW
Contest TW
Contest TW